Cerebrospinal fluid (CSF) analysis reveals that concentrations of total tau protein (t-Tau) and phosphorylated tau-181 (p-Tau 181) are significantly elevated in AD patients compared to DLB counterparts [31–33], but their discriminative power may be confounded by comorbid amyloid pathology in mixed cases [34]; therefore, these measures may function as potential discriminators between AD and DLB. The gene discussed is MAPT; the disease is Lewy body dementia.